Amendment Statement of Principles
concerning

SUBDURAL HAEMATOMA

No. 43 of 2019

for the purposes of the

Veterans' Entitlements Act 1986
and
Military Rehabilitation and Compensation Act 2004

1. This Instrument may be cited as Amendment Statement of Principles concerning subdural haematoma No. 43 of 2019.


(A) Repealing factors "(e)" and "(h)" in clause 6 and substituting the following:

"(e) undergoing antithrombotic therapy within the two weeks before the clinical onset of subdural haematoma; or"

"(h) undergoing antithrombotic therapy within the two weeks before the clinical worsening of subdural haematoma; or"

(B) Inserting new factors "(ea)" and "(ha)" following factors "(e)" and "(h)" respectively, in clause 6 as follows:

"(ea) taking at least 700 milligrams of aspirin within a seven day period before the clinical onset of subdural haematoma, where the last dose was received within the seven days before the clinical onset of subdural haematoma; or"

"(ha) taking at least 700 milligrams of aspirin within a seven day period before the clinical worsening of subdural haematoma, where the last dose was received within the seven days before the clinical worsening of subdural haematoma; or"
(C) Inserting the following definition of "antithrombotic therapy" in clause 9 in alphabetical order:

"antithrombotic therapy" means taking a drug for the treatment or prophylaxis of a thrombotic event, and includes antiplatelet drugs, anticoagulants and thrombolytic agents;

Note: Examples of drugs used in antithrombotic therapy include, but are not limited to, aspirin, clopidogrel, tirofiban, warfarin, heparin, dabigatran, apixaban, rivaroxaban and alteplase.; and

(D) Deleting the definition of "a drug from the specified list" in clause 9.

3. The amendments made by this instrument commence on 25 March 2019.

Dated 1 March 2019

The Common Seal of the Repatriation Medical Authority was affixed to this instrument at the direction of:

PROFESSOR NICHOLAS SAUNDERS AO CHAIRPERSON